Baird Financial Group Inc. Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Baird Financial Group Inc. boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 35.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,474 shares of the biopharmaceutical company’s stock after acquiring an additional 16,711 shares during the quarter. Baird Financial Group Inc.’s holdings in Intra-Cellular Therapies were worth $5,385,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ITCI. Accredited Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at $28,000. GAMMA Investing LLC raised its stake in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in Intra-Cellular Therapies in the fourth quarter valued at $96,000. Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies during the 3rd quarter worth about $97,000. Finally, Covestor Ltd boosted its position in shares of Intra-Cellular Therapies by 15.9% during the 4th quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock worth $175,000 after acquiring an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $131.87 on Friday. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98. The stock’s 50 day simple moving average is $131.73 and its 200-day simple moving average is $111.89. The firm has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ITCI. Piper Sandler restated a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Wednesday. They issued a “hold” rating for the company. Finally, Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.